Production of Modified Autologous Conditioned Serum and Ex Vivo Assessment of Its Healing Potential in Murine Corneal Epithelium

Summary

This article describes a protocol to simplify the process and render the preparation of autologous conditioned serum (ACS) less expensive. No special syringes or surface-coated glass beads are needed. Moreover, the modified ACS (mACS) has competitive advantages over conventional autologous serum in the corneal wound healing of murine eyes ex vivo.

Abstract

Human blood-derived topical therapies have been a boon to clinicians in recent decades. Autologous serum (AS) and platelet-rich plasma (PRP) are enriched in epitheliotropic growth factors that are essential in corneal wound healing. Unlike AS, PRP is based on a differential centrifugation system, yielding more platelet-derived growth factors. Autologous conditioned serum (ACS) not only preserves the preparation of AS and PRP, but also focuses on immune-modulating properties, which are important in inflammatory diseases.

The lack of standardized protocols and high preparation costs are limitations for the clinical application of ACS. This video experiment demonstrates a standard operating procedure for preparing modified autologous conditioned serum (mACS) eye drops. First, glycerol was added into heparin syringes as the blood cell stabilizer during hypoxic incubation. To activate the blood cells, a 4 h incubation at 37 °C was initiated. Then, the blood samples were centrifuged at 3,500 × g for 10 min at room temperature. After filtration of the supernatant through a 0.22 µm filter, the mACS eye drops were fully prepared.

A tentative try-out of the therapeutic effect of mACS showed that it may have competitive advantages over conventional AS in the corneal wound healing in ex vivo mouse eyes. The AS used in this study was prepared according to published studies and the clinical practice in our hospital. Therefore, the efficacy of mACS on ocular surface diseases could be evaluated in future research through in vivo animal studies and clinical trials.

Introduction

The therapeutic effects of autologous serum (AS) in dry eye diseases were first reported in the 1980s by Fox et al.¹. It is believed that both the lubricating property and the essential epitheliotropic biochemical components in AS, mimicking natural tears, benefit the proliferation of corneal epithelial cells. Over the past decades, several studies have been performed on this basis. Trophic components include epidermal growth factor (EGF), vitamin A, transforming growth factor β (TGF- β), and other cytokines. Interestingly, the serum is rich in TGF- β and vitamin A, which are believed to play a pivotal role in epidermal proliferation^2,3,4,5. In addition, when treating patients with ocular surface diseases, several studies have showed some advantages of AS eye drops in patient-reported outcomes, other objective dry eye parameters^6,7, and microscopic findings such as cell density⁸. Meta-analysis studies revealed that there might be some benefits in improving patient's syndromes with AS eye drops treatment, but long-term results and observations are still lacking^9,10.

Unlike AS, platelet-rich plasma (PRP) is derived from adding an anticoagulant during preparation, with further differential centrifugation and chemical activation of the platelets. Compared with AS, numerous chemicals and growth factors, such as TGF- β, vascular endothelial growth factor (VEGF), and EGF, are present in PRP. It has also been applied to ocular surface diseases with clinical benefits in symptom relief¹¹.

The cross-link between epithelial defects and inflammation is complex. Notably, immunopathophysiology is another important issue in ocular surface diseases. Pro-inflammatory cytokines, such as IL-1β and IFN-γ, are believed to be pivotal mediators in inflammatory cascades¹². New avenues of treatment are thus opened based on understanding the immune mechanism. Strategies to stop this inflammatory process, including the production of interleukin-1 receptor antagonist (IL-1Ra) and other anti-inflammatory cytokines, may also play an important role in ocular surface diseases^13,14,15.

Since 1998, Orthokine, a commercialized autologous conditioned serum (ACS), has been used clinically in orthopedic patients suffering from osteoarthritis (OA), rheumatoid arthritis (RA), and spinal disorders¹³. Compared with AS and PRP, treatment with chemically coated glass beads and hypoxic incubation to activate monocytes are the specific features of ACS¹⁶. Theoretically, more anti-inflammatory factors can be secreted by adding survival stress to the cells, resulting in a higher concentration of essential immune-modulating components, including IL-1Ra. The improved therapeutic benefits of ACS in OA, compared with AS, have also been reported¹⁷. Ocular surface diseases share similar immune backgrounds with orthopedic inflammatory diseases in some respects. Therefore, based on the successful results of human blood-derived therapy in the orthopedic field, ACS might have advantages over conventional treatments in clinical practice by epitheliotropic and immune-modulating properties. Although ACS has been widely used in orthopedic inflammatory diseases, its clinical applications in ophthalmology still need to be explored, which may be hindered by its high cost, lack of literature support, and lack of standardization of the preparation process, resulting in diverse performance.

In this video article, a novel, cost-effective, and convenient method was demonstrated to generate the modified ACS (mACS), or plasma rich in growth factors (PRGF), producing an eye drop solution with a comparable practical value to commercialized ACSs. The key ideas of adding anticoagulants and triggering the blood cells to secrete anti-inflammatory cytokines by stressed incubation were retained, but unlike the chemically-induced methods, such as those based on CrSO₄-coated glass beads and commercial kits, the critical stress status is physically induced by hypoxic incubation in this method. Moreover, glycerol was added to provide extra benefits, including an increase in the stability of the membrane of blood cells, maintenance of a proper osmotic extracellular fluid pressure¹⁸, and an appropriate source of nutrients in hypoxic conditions that avoid overstressing the cells.

Protocol

The research was performed in compliance with institutional guidelines at the beginning of the protocol section. All protocols and procedures were carried out according to the Declaration of Helsinki and were reviewed and approved by the Chang Gung Medical Foundation Institutional Review Board. All volunteers were informed of the nature of this study and signed an informed consent form prior to their inclusion. The consumables required for the entire experimental procedure are presented in Figure 1 and Figure 2, as well as in the Table of Materials.

1. Preparation of the materials needed to produce mACS eye drops

1. Prepare 250 mL of 10% glycerol solution and keep a 21 G butterfly-winged infusion set, a 3 mL syringe without the needle, and six 10 mL vacutainer tubes containing heparin 158 USP units ready (Figure 1).
2. Connect the 21 G blood collection needle to the 3 mL syringe and withdraw 3 mL of 10% glycerol solution into the prepared syringe.
   NOTE: All materials must be sterilized before the needle is inserted.
3. Distribute the 10% glycerol solution into the vacutainer tubes in sequence, with approximately 0.5 mL of 10% glycerol solution in each (Figure 3A).
   ​NOTE: Because of the negative pressure in the test tube, the needle must come out immediately after it goes in to evenly distribute 3 mL of glycerol solution to the six test tubes.
4. Sterilize the patient's skin with 75% alcohol sterile cotton swabs. Puncture the superficial vein of the patient's upper limbs with the 18 G blood collection needle. Draw 60-70 mL of venous blood from the superficial vein in total.

2. Preparation for mACS eye drops

1. Sequentially inject 10 mL of the drawn venous blood into each of the six vacutainer tubes (Figure 3B).
   NOTE: This step relies on the negative pressure of the vacuum to fill the tubes. To avoid blood cell disruption and hemolysis, do not apply any positive pressure.
2. Place the six vacutainer tubes in the incubator with a constant temperature of 37 °C for 4 h (Figure 3C).
   NOTE: The hypoxic status is maintained and stabilized by the remaining negative pressure in a sealed tube that received glycerol.
3. Remove the tubes from the incubator after 4 h and centrifuge them at 3,500 × g for 10 min at room temperature.
4. At this point, prepare the materials for mACS extraction, including the sterilized eye drop bottles, a 3 mL syringe with the needle, a 0.22 µm filter, an 18 G needle, and a pair of sterile gloves (Figure 2).
   NOTE: The operating table should be wiped with 75% alcohol to ensure an aseptic environment. The supernatant, after centrifugation, is already a semi-finished product of mACS.
5. Place the six tubes on the tube rack and open the caps after complete centrifugation (Figure 3D).
   NOTE: Sterility is not required in this step.
6. Put on sterile gloves and draw out the mACS one by one using a 3 mL syringe with an 18 G needle.
   NOTE: Be careful not to draw the lower blood cell layer during this step (Figure 3E).
7. Pull out the needle, connect it to the 0.22 µm filter, and connect the 23 G, 1.5 in blood collection needle with the original 3 mL syringe to the outlet below (Figure 3F).
8. Push the needle gently through the 0.22 µm filter into the prepared sterile eye drop bottles (Figure 3G).
9. Repeat the above steps until all the mACS has been filtered and stored in eye drop bottles (Figure 3H).
10. Store the mACS eye drops at 4 °C for immediate use; store at -20 °C for long-term preservation.
    ​NOTE: Do not keep them for more than 2 weeks at 4 °C or for longer than 3 months at -20 °C^9,19.

3. Ex vivo wound healing model of murine corneal epithelium

NOTE: The following ex vivo animal model was based on prior experience from Hung et al. on mechanical injuries of the corneal epithelium²⁰. The following steps should be performed under the microscope to create a well-circumscribed and consistent corneal epithelial wound.

1. Anesthetize the C57BL/6 mice with 3%-4% isoflurane. Indent the skin biopsy punch over the murine central cornea, leaving a shallow circle on the epithelium as a uniform wound margin.
   NOTE: Be gentle to avoid eyeball rupture.
2. Debride the corneal epithelium within the confirmed area down to the Bowman's layer, with a corneal rust ring remover equipped with a 0.5 mm burr.
3. To establish the ex vivo animal model of the mechanical corneal wound, harvest the eyeball and prepare the culture well.
   1. Euthanize the mice first; then, gently press the superior and inferior orbital rims of the mice, introduce the tip of the forceps over the retrobulbar space, and out the eyeball and hold it by the forceps.
   2. Cut the optic nerve and periorbital soft tissue with corneal scissors to isolate the eyeball perfectly.
   3. Prepare a 96-well plate with melted wax inside it. Quickly create a round hole using the tips of forceps and then wait for solidification.
4. Prepare the media to be tested: 0.5% mACS, 0.5% AS for comparison, normal saline as a negative control, and Dulbecco's modified Eagle's medium (DMEM).
   NOTE: mACS is obtained using the protocol mentioned above.
5. For the ex vivo culture, place the harvested eyeball onto the prepared 96-well plate. Add 200 µL of each medium into the 96-well plate.
6. Place the 96-well culture plate into the incubator at 37 °C with 5% CO₂. Ensure that the culture media is changed every 24 h.
7. To confirm the sequential wound healing effect, monitor the epithelial wound area under the microscope every 8 h by fluorescein staining.
   1. Dissolve the fluorescein on the fluorescein paper with normal saline.
   2. Drop the fluorescein dye onto the murine central cornea, then observe and document it under a microscope. A typical result is shown in Figure 4.
      NOTE: One drop (approximately 0.05 mL) of fluorescein dye is enough for the observation.

Results

Figure 1 and Figure 2 show the materials needed for the experiment, and Figure 3 displays the sequential steps and the successful mid-products during the preparation of mACS. First, 0.5 mL of 10% glycerol solution was added into each 10 mL sterile test tube (Figure 3A). Then, 60-70 mL of venous blood was obtained from the patient, and 10 mL of blood was injected into each tube (

Discussion

In this study, a protocol for the preparation of mACS is described and the benefit of mACS eye drops in the wound healing of animal models is further shown. The crucial modification of this mACS protocol is the addition of approximately 0.5 mL of 10% glycerol solution in each test tube, which creates suitable hypoxic conditions during the 4 h incubation at 37 °C. This setting provides the AS with proper stress and prompt cells to secrete the necessary growth factors that help wound healing. The 0.22 µm filter c...

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
96-well culture plate	Merck KGaA, Germany	CLS3997
Barraquer lid speculum	katena	K1-5355	15 mm
Barraquer needle holder	Katena	K6-3310	without lock
Barron Vacuum Punch 8.0 mm	katena	K20-2108	for cutting filter paper
BD 10.0 mL vacutainer tubes containing heparin 158 USP units	Becton,Dickinson and Company, US	367880	At least 6 tubes, necessary to collect blood for subsequent experiments and to avoid blood agglutination
BD 21 G butterfly-winged infusion set	Becton,Dickinson and Company, US	367281	For even distribution of glycerol solution
C57BL/6 mice	National Laboratory Animal Center	RMRC11005	for mouse model
Castroviejo forceps 0.12 mm	katena	K5-2500
Centrifuge	Eppendorf, Germany	5811000428	3,500 x g for 10 min
Cheng Yi 10.0 mL sterilized eye dropper bottle	Cheng Yi Chemical, Taiwan	CP405141	Must be sterile and as the storage container for the final product
Corneal rust ring remover with 0.5 mm burr	Algerbrush IITM; Alger Equipment Co., Inc. Lago Vista, TX	CHI-675	for debridement of the corneal epithelium
Dulbecco's modified minimal essential medium	Merck KGaA, Germany	D6429
Filter paper	Toyo Roshi Kaisha,Ltd.	1.11
Fluorescein sodium ophthalmic strips U.S.P	OPTITECH	OPTFL100	staining for corneal epithelial defect
Incubator	Firstek, Taiwan	S300S	37 °C for 4 h
Kanam sterile gloves	Kanam Latex Industries, India	EN455	For aseptic operation
Merck 0.22 µm filter	Merck KGaA, Germany	PR05359	At least 2 filters for mACS filtration
Nang Kuang 250 mL 10% glycerol solution	Nang Kuang Pharmaceutical, Taiwan	19496	To offer suitable membrane stabilization effect and extracellular osmotic pressure for blood cells
Normal saline	TAIWAN BIOTECH CO., LTD.	100-120-1101
Skin biopsy punch 2mm	STIEFEL	22650
Stereomicroscope	Carl Zeiss Meditec, Dublin, CA	SV11	microscope for surgery
Terumo 18 G needle	Terumo, Taiwan	SMACF0120-18BX	3.0 mL syringe with 18 G needle to extract the supernatant after centrifugation
Terumo 20.0 mL syringe	Terumo, Taiwan	MDSS20ES	Could be used to collect serum after initial centrifugation and use it for secondary centrifugation.
Terumo 3.0 mL syringe with the 23 G needle	Terumo, Taiwan	MDSS03S2325	3.0 mL syringe is used to extract the supernatant after centrifugation. Then connect the filter and the 23 G needle for injection into the eye drop bottles.
Westcott Tenotomy Scissors Medium	katena	K4-3004